Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sirona Biochem Corp
V.SBM
Alternate Symbol(s):
SRBCF
Healthcare
Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to...
large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:SBM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(11)
•••
LakeOromocto
X
View Profile
View Bullboard History
Post by
LakeOromocto
on Nov 22, 2024 3:55am
New post on X
https://drive.google.com/file/d/12_pQro1PUpHqHTXvmOIA9lHewIjAmFbZ/view
(76)
•••
Pareto8020
X
View Profile
View Bullboard History
Comment by
Pareto8020
on Nov 21, 2024 7:45pm
RE:DAMMIT! WRONG AGAIN!
What will it take = Revenue. They need to start getting royalties and product sales before the market is going to give them any respect or chance of putting a dollar sign in front of
...more
(2099)
•••
tylerreddick
X
View Profile
View Bullboard History
Comment by
tylerreddick
on Nov 21, 2024 5:33pm
RE:DAMMIT! WRONG AGAIN!
Gain one cent? We couldn't even get any volume on NO gain.
(80)
•••
bealert
X
View Profile
View Bullboard History
Post by
bealert
on Nov 21, 2024 4:19pm
DAMMIT! WRONG AGAIN!
Sorry folks about getting your hopes up. We couldn't even gain one cent on the reinstatement of recent news. What will it take??? Years and years of frustration no matter how much we hope
...more
(72)
•••
MirrorWorldMan
X
View Profile
View Bullboard History
Comment by
MirrorWorldMan
on Nov 21, 2024 3:59pm
RE:RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
Well that publication announcement explains the recent Volume jump, likely due to an overzealous expectations. Looks like some more investors got taken.
(33)
•••
SleepyHoward
X
View Profile
View Bullboard History
Comment by
SleepyHoward
on Nov 21, 2024 10:33am
RE:RE:RE:RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
It looks not like that
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(80)
•••
bealert
X
View Profile
View Bullboard History
Comment by
bealert
on Nov 20, 2024 11:08pm
RE:RE:RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
I'm betting that this positive and informative news release will raise the share price by at least one cent, maybe more! I'm excited as 1 cent translates to about 15% increase.
...more
(1156)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Nov 20, 2024 10:46pm
RE:RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
There is a slight difference: The April news release was reporting the results of the study. Today's news release is announcing the publication of the study in the prestigious Journal of
...more
(2099)
•••
tylerreddick
X
View Profile
View Bullboard History
Comment by
tylerreddick
on Nov 20, 2024 10:36pm
RE:RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
To be fair, this news release was about the publication of the findings in the mentioned Journal. They didn't say it was a new study. Any public exposure is a good thing as we wait for funding.
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Nov 20, 2024 7:53pm
RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
This is not news. Results were disclosed in April 2023. Where the hell are the results of trials with Sirona Labs formulations which Geraldine said would be done in H2 2024? https://stockhouse.com
...more
(26)
•••
24minus7
X
View Profile
View Bullboard History
Post by
24minus7
on Nov 20, 2024 6:44pm
Promising Teamwork Approach
A new approach: Instead of just covering up wrinkles, TFC-1326 tries to tackle what causes skin to age in the first place. It does this by encouraging the skin to repair itself and make more
...more
(2099)
•••
tylerreddick
X
View Profile
View Bullboard History
Comment by
tylerreddick
on Nov 20, 2024 5:57pm
RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
“We are actively advancing discussions with potential commercial partners" If Howie ever gets a backer, we will be off to the races. But it should have already been done by now. And wasn't
...more
(1156)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Nov 20, 2024 4:43pm
RE:New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
A positive article. Will it move the needle? I sure hope so -- I could use a positive move somewhere, anywhere! I am sick and tired of my stocks being sick and tired.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 20, 2024 4:30pm
New Press Release - Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology.About the StudyThe article, titled “TFC-1326 Compound Reduces Clinical...
read article.
(2099)
•••
tylerreddick
X
View Profile
View Bullboard History
Post by
tylerreddick
on Nov 20, 2024 2:36pm
New tweet, bfd
https://x.com/SironaBiochem/status/1859121777881846051
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >